ReviewCancers2021
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Simultaneous Risk-Reducing Mastectomy and Salpingo-Oophorectomy in Patients withJournal of personalized medicine · 2026Article
- Knowledge, attitudes and practices of cancer genetics in family medicine in Japan: a mixed methods study.BMC primary care · 2026Article
- A knowledge, attitudes, and practices study on BRCA mutations among family members of women diagnosed with epithelial ovarian or fallopian tube cancer.Obstetrics & gynecology science · 2025Article
- SPACA6P-AS: a trailblazer in breast cancer pathobiology and therapeutics.Cell biology and toxicology · 2024Article
- Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.Frontiers in oncology · 2024Review
- Challenges for clinical application of "TRACEBACK" study: testing of historical Tubo-Ovarian cancer patients for hereditary risk genes.Annals of translational medicine · 2023Article
- The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery inCurrent oncology (Toronto, Ont.) · 2023Review
- Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.International journal of environmental research and public health · 2022Review
- Review
- Differences in age at diagnosis of ovarian cancer for eachJournal of gynecologic oncology · 2022Article
- Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.Journal of human genetics · 2022Article
- Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.Frontiers in oncology · 2022Article
- Primary and metastatic peritoneal surface malignancies.Nature reviews. Disease primers · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the field of gynecology, the approval of the PARP inhibitors (PARPi) has been changing the treatment of ovarian cancer patients. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.